South Korea’s Genexine to initiate phase 1 trials of DNA vaccine against COVID-19

South Korea-based Genexine has announced that it is the first domestic pharmaceutical company to have been approved for clinical phase 1/2a of GX-19, which is a DNA vaccine against COVID-19, by the country’s Ministry of Food and Drug Safety. 
This trial, according to the company, will be proceeded to phase 1 in 40 healthy volunteers in two dose levels The study will evaluate the safety and efficacy of antibody formation in 150 patients, including placebo, in one dose in phase 2a.
The company expects the phase 1 of clinical trials to be completed within 3 months. Genexine hopes to expand the phase 2 phase of clinical trials to multinational sites, including countries where the spread of COVID-19 is severe. 
Young Chul Sung, CEO, said, "We are working with several domestic and foreign partners including Binex to secure vaccine supply, and we will accelerate our preparations to supply sufficient amounts not only in Korea but also in countries with insufficient vaccines." 
Genexine is currently the only company that simultaneously develops preventive vaccines and treatments for COVID-19 by collaborating with NIT and approved US clinical trials of Hyleukin-7 for COVID-19 patients. It is one of three vaccine development companies supported by the Government of South Korea.

Genexine received approval for clinical phase 1/2a of GX-19, a DNA vaccine against COVID-19, by the country’s Ministry of Food and Drug Safety.

Recommended News